Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma

Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James M. Provenzale, Roger E. McLendon, Sridharan Gururangan, Darell D. Bigner, James E. Herndon,

Journal of Clinical Oncology · 2003 · 254 citations · 34 references

Abstract

Initial results indicate that Temodar may be active in the treatment of low-grade glioma, and thus, further evaluation of this agent in the treatment of these tumors is warranted.

References

34